Taro receives FDA approval for Kytril generic

HAWTHORNE, N.Y. Taro Pharmaceutical Industries has received approval from the Food and Drug Administration to market its generic version of a drug used to prevent nausea and vomiting in patients on chemotherapy, the Israeli generic drug maker said Friday.

The FDA approved Taro’s granisetron hydrochloride tablets in the 1-mg strength. The tablets are a generic version of Roche’s Kytril tablets.

Granisetron tablets had sales of around $15 million in 2009, according to unnamed industry sources cited by Taro.

Login or Register to post a comment.